[Skip navigation] FDA, Office of Planning

Report on PDUFA Goals: Resubmitted New Product Applications

Goal: Review and act upon resubmitted NDAs and BLAs

A resubmission is a firm's response after an FDA action of "approvable," "not approvable," or "complete response" on an application. The applicable performance goal for a resubmission is determined by the year in which the resubmission itself is received, rather than its original application's year of submission. The definitions of Class 1 and Class 2 resubmissions can be found at the end of Appendix B.

Goals

On-Time Performance by Resubmission Year

FY 98

FY 99

FY 00

FY 01

FY 02

Class 1

6 months

4 months

2 months

90% on time

 

30%

 

90%

50%

 

90%

70%

 

 

90%

 

 

90%

Class 2

6 months

90%

90%

90%

90%

90%

 

Workload

Workload -- Resubmissions received [Total (Class 1/Class 2)]

FY 96

FY 97

FY 98

FY 99

FY 00

of Original NDAs

84

82

50 (19/31)

63 (17/46)

77 (26/51)

of Original BLAs

14

8

21 (5/16)

14 (2/12)

9 (1/8)

PDUFA Total

98

90

71 (24/47)

77 (19/58)

86 (27/59)

Performance:

FY 99 Submissions:

All 19 Class 1 resubmissions received in FY 99 were reviewed and acted upon within 2 months, and all 58 Class 2 resubmissions were reviewed and acted upon within 6 months. Review performance on both classes of FY 99 resubmissions exceeded the PDUFA review goals.

FY 99 Resubmissions

Reviewed and acted upon

Number on time

Percent on time

Class 1

4 months

2 months

19

19

19

100

100

Class 2

6 months

58

58

100

FY 00 Submissions:

As of September 30, 2000, 23 FY 00 Class 1 resubmissions had been reviewed and acted upon. All 23 met the 4-month review goal, and all but one met the 2-month goal. With only 4 Class 1 resubmissions still pending, review performance on FY 00 Class 1 resubmissions will exceed the review goals.

All but one of the Class 2 resubmissions that have been reviewed and acted upon have met the 6 month goal. While too many are still pending to make a final performance determination, current on-time performance stands at 97 percent.

FY 00 Resubmissions

Reviewed and acted upon

Number on time

Percent on time

Class 1

4 months

2 months

23

23

22

100

96

Class 2

6 months

30

29

97



Next Page | Table of Contents | Previous Page



FDA Home Page
| Search | A-Z Index | Site Map | Contact FDA

FDA/Office of Planning
Web page created by cm 2001-MAR-01.